{"id":734,"date":"2020-08-29T11:47:33","date_gmt":"2020-08-29T15:47:33","guid":{"rendered":"https:\/\/ecogene21.org\/?post_type=nouvelle&p=734"},"modified":"2025-10-21T16:19:00","modified_gmt":"2025-10-21T20:19:00","slug":"levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale","status":"publish","type":"nouvelle","link":"https:\/\/ecogene21.org\/fr\/nouvelle\/levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale\/","title":{"rendered":"L’\u00e9volocumab r\u00e9duit de 44 % le taux de LDL-C chez les enfants atteints d’hypercholest\u00e9rol\u00e9mie familiale"},"content":{"rendered":"

Evolocumab (Repatha) significantly improved low-density lipoprotein cholesterol (LDL-C) levels in pediatric patients with familial hypercholesterolemia, according to a new study.<\/p>\n

The phase 3 findings, presented during a late-breaking session at the European Society of Cardiology (ESC) 2020 Congress this weekend, give clinicians incentive to further understand the benefit of the PCSK9 inhibitor drug class among children suffering from the most common monogenic disorder in the world.<\/p>\n","protected":false},"excerpt":{"rendered":"

Evolocumab (Repatha) significantly improved low-density lipoprotein cholesterol (LDL-C) levels in pediatric patients with familial hypercholesterolemia, according to a new study. The phase 3 findings, presented during a late-breaking session at the European Society of Cardiology (ESC) 2020 Congress this weekend, give clinicians incentive to further understand the benefit of the PCSK9 inhibitor drug class among […]<\/p>\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":false,"inline_featured_image":false},"categorie":[14],"class_list":["post-734","nouvelle","type-nouvelle","status-publish","hentry","categorie-actualites"],"acf":[],"yoast_head":"\nL'\u00e9volocumab r\u00e9duit de 44 % le taux de LDL-C chez les enfants atteints d'hypercholest\u00e9rol\u00e9mie familiale - ECOGENE-21<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ecogene21.org\/fr\/nouvelle\/levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"L'\u00e9volocumab r\u00e9duit de 44 % le taux de LDL-C chez les enfants atteints d'hypercholest\u00e9rol\u00e9mie familiale - ECOGENE-21\" \/>\n<meta property=\"og:description\" content=\"Evolocumab (Repatha) significantly improved low-density lipoprotein cholesterol (LDL-C) levels in pediatric patients with familial hypercholesterolemia, according to a new study. The phase 3 findings, presented during a late-breaking session at the European Society of Cardiology (ESC) 2020 Congress this weekend, give clinicians incentive to further understand the benefit of the PCSK9 inhibitor drug class among […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ecogene21.org\/fr\/nouvelle\/levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale\/\" \/>\n<meta property=\"og:site_name\" content=\"ECOGENE-21\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ecogene21\/\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-21T20:19:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ecogene21.org\\\/fr\\\/nouvelle\\\/levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale\\\/\",\"url\":\"https:\\\/\\\/ecogene21.org\\\/fr\\\/nouvelle\\\/levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale\\\/\",\"name\":\"L'\u00e9volocumab r\u00e9duit de 44 % le taux de LDL-C chez les enfants atteints d'hypercholest\u00e9rol\u00e9mie familiale - ECOGENE-21\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ecogene21.org\\\/fr\\\/#website\"},\"datePublished\":\"2020-08-29T15:47:33+00:00\",\"dateModified\":\"2025-10-21T20:19:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ecogene21.org\\\/fr\\\/nouvelle\\\/levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ecogene21.org\\\/fr\\\/nouvelle\\\/levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ecogene21.org\\\/fr\\\/nouvelle\\\/levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\\\/\\\/ecogene21.org\\\/fr\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"L’\u00e9volocumab r\u00e9duit de 44 % le taux de LDL-C chez les enfants atteints d’hypercholest\u00e9rol\u00e9mie familiale\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ecogene21.org\\\/fr\\\/#website\",\"url\":\"https:\\\/\\\/ecogene21.org\\\/fr\\\/\",\"name\":\"ECOGENE-21\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/ecogene21.org\\\/fr\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ecogene21.org\\\/fr\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/ecogene21.org\\\/fr\\\/#organization\",\"name\":\"ECOGENE-21\",\"url\":\"https:\\\/\\\/ecogene21.org\\\/fr\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/ecogene21.org\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/ecogene21.org\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Ecogene_Logo.svg\",\"contentUrl\":\"https:\\\/\\\/ecogene21.org\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/Ecogene_Logo.svg\",\"width\":\"1024\",\"height\":\"1024\",\"caption\":\"ECOGENE-21\"},\"image\":{\"@id\":\"https:\\\/\\\/ecogene21.org\\\/fr\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ecogene21\\\/\",\"https:\\\/\\\/ca.linkedin.com\\\/company\\\/ecogene-21\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"L'\u00e9volocumab r\u00e9duit de 44 % le taux de LDL-C chez les enfants atteints d'hypercholest\u00e9rol\u00e9mie familiale - ECOGENE-21","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ecogene21.org\/fr\/nouvelle\/levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale\/","og_locale":"fr_FR","og_type":"article","og_title":"L'\u00e9volocumab r\u00e9duit de 44 % le taux de LDL-C chez les enfants atteints d'hypercholest\u00e9rol\u00e9mie familiale - ECOGENE-21","og_description":"Evolocumab (Repatha) significantly improved low-density lipoprotein cholesterol (LDL-C) levels in pediatric patients with familial hypercholesterolemia, according to a new study. The phase 3 findings, presented during a late-breaking session at the European Society of Cardiology (ESC) 2020 Congress this weekend, give clinicians incentive to further understand the benefit of the PCSK9 inhibitor drug class among […]","og_url":"https:\/\/ecogene21.org\/fr\/nouvelle\/levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale\/","og_site_name":"ECOGENE-21","article_publisher":"https:\/\/www.facebook.com\/ecogene21\/","article_modified_time":"2025-10-21T20:19:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ecogene21.org\/fr\/nouvelle\/levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale\/","url":"https:\/\/ecogene21.org\/fr\/nouvelle\/levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale\/","name":"L'\u00e9volocumab r\u00e9duit de 44 % le taux de LDL-C chez les enfants atteints d'hypercholest\u00e9rol\u00e9mie familiale - ECOGENE-21","isPartOf":{"@id":"https:\/\/ecogene21.org\/fr\/#website"},"datePublished":"2020-08-29T15:47:33+00:00","dateModified":"2025-10-21T20:19:00+00:00","breadcrumb":{"@id":"https:\/\/ecogene21.org\/fr\/nouvelle\/levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ecogene21.org\/fr\/nouvelle\/levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ecogene21.org\/fr\/nouvelle\/levolocumab-reduit-de-44-le-taux-de-ldl-c-chez-les-enfants-atteints-dhypercholesterolemie-familiale\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ecogene21.org\/fr\/"},{"@type":"ListItem","position":2,"name":"L’\u00e9volocumab r\u00e9duit de 44 % le taux de LDL-C chez les enfants atteints d’hypercholest\u00e9rol\u00e9mie familiale"}]},{"@type":"WebSite","@id":"https:\/\/ecogene21.org\/fr\/#website","url":"https:\/\/ecogene21.org\/fr\/","name":"ECOGENE-21","description":"","publisher":{"@id":"https:\/\/ecogene21.org\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ecogene21.org\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ecogene21.org\/fr\/#organization","name":"ECOGENE-21","url":"https:\/\/ecogene21.org\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ecogene21.org\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ecogene21.org\/wp-content\/uploads\/2025\/07\/Ecogene_Logo.svg","contentUrl":"https:\/\/ecogene21.org\/wp-content\/uploads\/2025\/07\/Ecogene_Logo.svg","width":"1024","height":"1024","caption":"ECOGENE-21"},"image":{"@id":"https:\/\/ecogene21.org\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ecogene21\/","https:\/\/ca.linkedin.com\/company\/ecogene-21"]}]}},"_links":{"self":[{"href":"https:\/\/ecogene21.org\/fr\/wp-json\/wp\/v2\/nouvelle\/734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ecogene21.org\/fr\/wp-json\/wp\/v2\/nouvelle"}],"about":[{"href":"https:\/\/ecogene21.org\/fr\/wp-json\/wp\/v2\/types\/nouvelle"}],"wp:attachment":[{"href":"https:\/\/ecogene21.org\/fr\/wp-json\/wp\/v2\/media?parent=734"}],"wp:term":[{"taxonomy":"categorie","embeddable":true,"href":"https:\/\/ecogene21.org\/fr\/wp-json\/wp\/v2\/categorie?post=734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}